SM 2880
Alternative Names: SM-2880Latest Information Update: 11 Dec 2023
At a glance
- Originator Beijing StarMab BioMed Technology
- Class Eye disorder therapies; Single-domain antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Diabetic macular oedema
Most Recent Events
- 01 Nov 2023 Early research in Diabetic macular oedema in China (Parenteral) (Beijing StarMab Biomed Technology pipeline; October 2023)